{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:18:26Z","timestamp":1790673506272,"version":"4.1.0"},"reference-count":39,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:00:00Z","timestamp":1554249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>No practical biomarkers currently exist for the prediction of the analgesic efficacy of opioids. Previously, we reported circulating miRNA signatures differentially regulated by \u00b5-opioid receptor (MOR) agonists in healthy subjects. We hypothesized that these miRNAs could be potential pharmacodynamic biomarkers to estimate MOR stimulation, and predict the efficacy of opioids; i.e., patients with low MOR stimulation may be more vulnerable to strengthening of the MOR signal upon hydromorphone treatment. To test this hypothesis, plasma samples were obtained from 25 patients with cancer pain prior to the initiation of hydromorphone treatment and the circulating miRNA levels were evaluated, focusing on four miRNAs (i.e., hsa-miR-423-3p, hsa-let-7a-5p, hsa-miR-26a-5p, and hsa-let-7f-5p) and four miRNAs (i.e., hsa-miR-144-3p, hsa-miR-451a, hsa-miR-215, and hsa-miR-363-3p) that were most clearly up and downregulated by hydromorphone and oxycodone. The patients were classified into two classes with putative high and low MOR signal, estimated based on the plasma miRNA signature. A significant correlation was observed between the analgesic efficacy and the putative MOR signal level, and patients with low MOR signal achieved better pain control (i.e., \u0394VAS &lt; 0) through hydromorphone. These results suggested that plasma miRNA signatures could serve as clinical biomarkers for the prediction of the analgesic efficacy of hydromorphone.<\/jats:p>","DOI":"10.3390\/ijms20071665","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T03:13:42Z","timestamp":1554347622000},"page":"1665","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Circulating miRNA Signature as a Potential Biomarker for the Prediction of Analgesic Efficacy of Hydromorphone"],"prefix":"10.3390","volume":"20","author":[{"given":"Naoki","family":"Kiyosawa","sequence":"first","affiliation":[{"name":"Specialty Medicine Research Laboratories I, Daiichi Sankyo Co., Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0301-8906","authenticated-orcid":false,"given":"Kenji","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Biomarker Department, Daiichi Sankyo Co., Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Toyama","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, Daiichi Sankyo Co., Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Ishizuka","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, Daiichi Sankyo Co., Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,4,3]]},"reference":[{"key":"ref_1","first-page":"CD012592","article-title":"Opioids for cancer pain\u2014An overview of Cochrane reviews","volume":"7","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.36076\/ppj.2008\/11\/237","article-title":"Variations in opioid responsiveness","volume":"11","author":"Smith","year":"2008","journal-title":"Pain Phys."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1002\/cncr.31303","article-title":"Cancer pain management and the opioid crisis in America: How to preserve hard-earned gains in improving the quality of cancer pain management","volume":"124","author":"Paice","year":"2018","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1208\/s12248-008-9056-1","article-title":"Opioid tolerance development: A pharmacokinetic\/pharmacodynamic perspective","volume":"10","author":"Dumas","year":"2008","journal-title":"Aaps J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/phar.1986","article-title":"Review of Opioid Pharmacogenetics and Considerations for Pain Management","volume":"37","author":"Hamadeh","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/0885-3924(95)90924-C","article-title":"Opioid rotation for toxicity reduction in terminal cancer patients","volume":"10","author":"Bruera","year":"1995","journal-title":"J. Pain Symptom Manag."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00520-005-0843-2","article-title":"No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients","volume":"14","author":"Riley","year":"2006","journal-title":"Support Care Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jpainsymman.2009.06.001","article-title":"Opioid rotation: The science and the limitations of the equianalgesic dose table","volume":"38","author":"Knotkova","year":"2009","journal-title":"J. Pain Symptom Manag."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jpain.2012.10.016","article-title":"Personalized medicine and opioid analgesic prescribing for chronic pain: Opportunities and challenges","volume":"14","author":"Bruehl","year":"2013","journal-title":"J. Pain"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis","volume":"15","author":"Ha","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/jcp.25056","article-title":"MicroRNA as Biomarkers and Diagnostics","volume":"231","author":"Wang","year":"2016","journal-title":"J. Cell Physiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1007\/s00204-016-1828-2","article-title":"Recent progress toward the use of circulating microRNAs as clinical biomarkers","volume":"90","author":"Ghai","year":"2016","journal-title":"Arch. Toxicol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.tins.2012.01.004","article-title":"MicroRNAs in neuronal function and dysfunction","volume":"35","author":"Im","year":"2012","journal-title":"Trends Neurosci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/1871527314666150116123932","article-title":"MicroRNAs: Emerging role in the endogenous mu opioid system","volume":"14","author":"Barbierato","year":"2015","journal-title":"Cns Neurol Disord. Drug Targets"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.06.001","article-title":"MicroRNA and chronic pain: From mechanisms to therapeutic potential","volume":"180","author":"Landry","year":"2017","journal-title":"Pharm. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7129","DOI":"10.1007\/s12035-016-0235-2","article-title":"Circulating microRNA Profiles as Liquid Biopsies for the Characterization and Diagnosis of Fibromyalgia Syndrome","volume":"54","author":"Masotti","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1007\/s12035-015-9106-5","article-title":"Serum MicroRNA Signatures in Migraineurs During Attacks and in Pain-Free Periods","volume":"53","author":"Andersen","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1136\/annrheumdis-2013-204698","article-title":"Signature of circulating microRNAs in osteoarthritis","volume":"74","author":"Beyer","year":"2015","journal-title":"Ann. Rheum Dis."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Bjersing, J.L., Lundborg, C., Bokarewa, M.I., and Mannerkorpi, K. (2013). Profile of cerebrospinal microRNAs in fibromyalgia. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0078762"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1007\/s12035-015-9281-4","article-title":"Circulating microRNA Signatures in Rodent Models of Pain","volume":"53","author":"Qureshi","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.neuron.2014.02.011","article-title":"Extracellular microRNAs activate nociceptor neurons to elicit pain via TLR7 and TRPA1","volume":"82","author":"Park","year":"2014","journal-title":"Neuron"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Toyama, K., Kiyosawa, N., Watanabe, K., and Ishizuka, H. (2017). Identification of Circulating miRNAs Differentially Regulated by Opioid Treatment. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18091991"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev-genet-120213-092023","article-title":"A Uniform System for the Annotation of Vertebrate microRNA Genes and the Evolution of the Human microRNAome","volume":"49","author":"Fromm","year":"2015","journal-title":"Annu. Rev. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/jjco\/hyy046","article-title":"A double-blind, randomized comparative study to investigate the morphine to hydromorphone conversion ratio in Japanese cancer patients","volume":"48","author":"Inoue","year":"2018","journal-title":"Jpn J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Lopez, J.P., Diallo, A., Cruceanu, C., Fiori, L.M., Laboissiere, S., Guillet, I., Fontaine, J., Ragoussis, J., Benes, V., and Turecki, G. (2015). Biomarker discovery: Quantification of microRNAs and other small non-coding RNAs using next generation sequencing. BMC Med. Genom., 8.","DOI":"10.1186\/s12920-015-0109-x"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"10513","DOI":"10.1073\/pnas.0804549105","article-title":"Circulating microRNAs as stable blood-based markers for cancer detection","volume":"105","author":"Mitchell","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/1476-4598-9-306","article-title":"Serum microRNAs as non-invasive biomarkers for cancer","volume":"9","author":"Brase","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/nmeth.3014","article-title":"Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study","volume":"11","author":"Mestdagh","year":"2014","journal-title":"Nat. Methods"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1373\/clinchem.2015.239459","article-title":"Data Normalization Strategies for MicroRNA Quantification","volume":"61","author":"Schwarzenbach","year":"2015","journal-title":"Clin. Chem."},{"key":"ref_30","unstructured":"Chen, L., Heikkinen, L., Wang, C., Yang, Y., Sun, H., and Wong, G. (2018). Trends in the development of miRNA bioinformatics tools. Brief. Bioinform., 10."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Chen, X., Xie, D., Zhao, Q., and You, Z.H. (2017). MicroRNAs and complex diseases: From experimental results to computational models. Brief. Bioinform.","DOI":"10.1093\/bib\/bbx130"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.drugalcdep.2012.01.013","article-title":"Opioid receptor expression in human brain and peripheral tissues using absolute quantitative real-time RT-PCR","volume":"124","author":"Peng","year":"2012","journal-title":"Drug Alcohol. Depend."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.molmed.2017.12.004","article-title":"Focusing on the Opioid System for Addiction Biomarker Discovery","volume":"24","author":"Belzeaux","year":"2018","journal-title":"Trends Mol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"249","DOI":"10.36076\/ppj.2011\/14\/249","article-title":"Peripherally acting opioids and clinical implications for pain control","volume":"14","author":"Sehgal","year":"2011","journal-title":"Pain Phys."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"32651","DOI":"10.1038\/srep32651","article-title":"Platelets confound the measurement of extracellular miRNA in archived plasma","volume":"6","author":"Mitchell","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_36","unstructured":"(2019, April 02). Exiqon, Biofluids Guidelines (Version 4.0)\u2014Analyzing microRNAs in Liquid Biopsies. Available online: http:\/\/www.exiqon.com\/ls\/Documents\/Scientific\/microRNA-serum-plasma-guidelines.pdf."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Oka, S., Furukawa, H., Shimada, K., Hashimoto, A., Komiya, A., Fukui, N., Tsuchiya, N., and Tohma, S. (2017). Plasma miRNA expression profiles in rheumatoid arthritis associated interstitial lung disease. BMC Musculoskelet Disord., 18.","DOI":"10.1186\/s12891-017-1389-4"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/0300060516630852","article-title":"Differential expression of circulating microRNAs in blood and haematoma samples from patients with intracerebral haemorrhage","volume":"44","author":"Wang","year":"2016","journal-title":"J. Int. Med. Res."},{"key":"ref_39","unstructured":"(2019, April 02). Exiqon, Data Analysis Guide For the miRCURY LNA\u2122 Universal RT microRNA Ready-to-Use PCR Panels using Exiqon GenEx software Version 3 (February 2014). Available online: https:\/\/www.exiqon.com\/ls\/Documents\/Scientific\/Exiqon-data-analysis-guide.pdf."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/7\/1665\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:42:40Z","timestamp":1760186560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/7\/1665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,3]]},"references-count":39,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,4]]}},"alternative-id":["ijms20071665"],"URL":"https:\/\/doi.org\/10.3390\/ijms20071665","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,3]]}}}